Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
2009 Feb-Apr;30(1-2):42-59
8 Regulatory, commercial, and practical considerations in advancing underexplored peptide systems Scientific plausibility alone is insufficient to advance underexplored peptidereceptor systems into approved therapeutics
Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, et al
And of the few that exist (less than 10), they are either done in cell cultures or in rats
2023 Ludvik B, Giorgino F, Jodar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
US$ 26.11
US$ 29.19
US$ 29.63
US$ 27.28
US$ 22.25
